AGBL2 is a metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. It catalyses the removal of polyglutamate side chains attached through the gamma-carboxyl group of glutamate residues in the C-terminal tail of tubulin. It acts specifically on long side-chains and cannot remove the branching-point glutamate, so it trims the polyglutamate chain without erasing the modification site. It also removes polyglutamate residues from the carboxy-terminus of non-tubulin proteins such as MYLK.

The AGBL2 gene encodes a protein listed by UniProt as cytosolic carboxypeptidase 2 and assigned to the peptidase M14 family. HGNC places it in the M14 carboxypeptidases gene group. The protein localises to the cytosol and to the centriole, centrosome and basal body of the cilium. NCBI Gene describes it as predicted to enable metallocarboxypeptidase and tubulin binding activity and to take part in protein side chain deglutamylation. Its centriolar and ciliary basal body location fits a role in modifying the microtubule cytoskeleton.

The gene was previously named ATP/GTP binding protein like 2, and the symbol AGBL2 follows from that name. Other aliases are CCP2 and FLJ23598. A mouse ortholog, Agbl2, is recorded. AGBL3 is a related member of the same family. Researchers studying tubulin post-translational modification often work with AGBL2 alongside other carboxypeptidases and glutamylases.